Why do people take retatrutide and tesamorelin together?
They go after fat from two different directions. Retatrutide is Eli Lilly's experimental weight-loss peptide that works on three gut hormone signals at once, and tesamorelin is the growth hormone peptide approved as Egrifta to shrink the deep belly fat around the organs. Dr. Ashley Froese, a family medicine physician who runs the YouTube channel This Is Not Covered, walked through the pairing in a recent video, and her shorthand is the clearest we've heard: "Retatrutide is like a dimmer switch on how much energy you take in and burn, but it's just not very selective. Tesamorelin is a spotlight."
That's also why it isn't simply double the fat loss. Froese points out that people assume two fat-loss tools means twice the result, when they're really doing two different jobs. The rest of this page covers what each job is, where they can get in each other's way, and what to keep an eye on. If you're weighing other companions too, our roundup of what people pair with retatrutide covers the rest of the list.
What does retatrutide do, and what does it leave to you?
Retatrutide copies three signals your gut sends after a meal. GLP-1 tells your brain you've eaten and slows your stomach, GIP helps with insulin, and the third, glucagon, nudges your body to burn more energy. Froese calls that third signal the thing that sets it apart, because it raises the calories you burn at rest even while you're eating less, which is the opposite of what a diet alone tends to do. In Lilly's published mid-stage study, people on the top amount lost about 24% of their body weight in 48 weeks.
What it doesn't do is choose where the weight comes from. "It doesn't decide whether your body holds on to lean tissue and muscle mass," Froese says. "You decide that." In practice that means protein and strength work, the unglamorous pair every muscle-keeping plan comes back to. The scale can't tell muscle from fat, but the stairs can.
What does tesamorelin add for belly fat?
Tesamorelin is the one approved to shrink the deep belly fat around your organs, and it does it by getting your own pituitary gland to release more growth hormone. It's a full-length copy of growth hormone-releasing hormone, the signal your brain normally sends for that. Deep belly fat, the visceral kind packed around your organs, is dense with growth hormone receptors, which is why this one can aim where retatrutide can't. Froese describes growth hormone telling that fat to release what it's storing, calming the inflammation it gives off, and pushing its cells to burn energy off as heat. That last part comes from lab research on how growth hormone works, not from the tesamorelin trials themselves.
In the main study behind the Egrifta approval, visceral fat dropped about 15% in 26 weeks on tesamorelin, against a 5% rise on placebo, measured on CT scans. Two details from the label matter for this pairing. Tesamorelin barely moves the scale, so it changes where fat sits rather than what the scale says, and when people were switched to placebo the belly fat came back on their scans. Those studies were in adults with HIV, the group it's approved for.
What's the cortisol catch?
Visceral fat doesn't only carry growth hormone receptors, it also carries plenty of receptors for cortisol, the stress hormone, and cortisol tells that same fat to hold on. "A huge reason for having a lot of visceral fat is that high cortisol puts it there," Froese says. Research backs the link. In a study of women put through repeated lab stress, the women who carried more fat around the middle released more cortisol, the lean ones included.
Her concern is what happens when a GLP-1 drug makes the body feel short on food. In her own practice she's seen some people on these drugs react the way you'd react to a threat, sleeping badly or catching one virus after another, which reads to her as a stress response. If that comes with extra cortisol, the same fat cell gets two opposite orders, burn from tesamorelin and store from cortisol. "It's kind of like trying to drain a bathtub while the faucet's still running," she says, and she frames it as a theory built from what she sees, not a measured result.
GLP-1 signals have been shown to nudge the body's stress hormone system in short studies in animals and people, though a 2024 study found that didn't explain why some people with type 2 diabetes respond poorly to these drugs. And tesamorelin's own label notes that growth hormone slows the enzyme fat tissue uses to turn cortisol on, so the tug of war may not be one-sided. Froese's fix is the plain one, regular exercise as the first move to bring cortisol down.
What side effects come with each one?
On the retatrutide side, Froese lists the familiar GLP-1 set: nausea, reflux, constipation or loose stools, and dehydration. She adds that fatigue, headaches or cramping can be a clue you're low on sodium. Lilly's trials also found a rise in resting heart rate that peaked around week 24 and then eased, which our answer on a racing heart on retatrutide covers. The burning, sunburn-like skin feeling she mentions shows up in Lilly's late-stage trials too, where it's called dysesthesia and was mostly mild. She also hears about flares of body and knee pain, which is reported experience, and in Lilly's trial in people with knee arthritis, knee pain went down on average.
Tesamorelin's label lists fluid retention as a common effect, showing up as swelling, joint aches and carpal tunnel symptoms like tingling hands. Froese has heard from several people who sleep worse on it, which she finds odd given growth hormone's link to deep sleep. She also flags serious allergic reactions, anaphylaxis included, as a risk across this whole family of peptides that doesn't get talked about enough, and the label puts hypersensitivity reactions at 4% in its trials, mostly itching, redness and rash, with advice to get medical help if one happens. Because growth hormone is a growth factor, the label rules tesamorelin out for anyone with active cancer, the theoretical tumor risk Froese mentions.
Where the two overlap is blood sugar, and they pull in opposite directions. Retatrutide lowers it, while tesamorelin can raise it, with the label reporting an A1C (the three-month blood sugar average) of 6.5% or higher in 5% of people on it, against 1% on placebo. Nobody has measured what the pair does together, which is one reason the blood work to ask about on a GLP-1 is useful if you're on both. Our guide to retatrutide side effects goes further on that half.
How do you compare prices when you're buying two?
Two compounds means two vials to price and two lab reports to check, and the gap between vendors matters twice. Compare the cost per milligram rather than the vial price, since vial sizes differ, then look for a vendor that publishes independent third-party testing for the batch you're buying. We track 41 vendors with retatrutide and 48 with tesamorelin, and the price comparison tool lines them up side by side. The vendor directory shows the confidence label we give each one, and the retatrutide dosage page and tesamorelin dosage page give the amounts each comes in, with a source for every one.
What isn't known yet about taking them together?
No study has tested retatrutide and tesamorelin together, so everything about the pairing, Froese's view included, is reasoning from each one on its own. Retatrutide isn't approved anywhere yet, and Lilly has said it plans to file with the FDA in early 2027. Tesamorelin's trials were in adults with HIV, and how its belly-fat results carry over to everyone else is much less studied. The cortisol idea is a clinician's theory from what she sees in practice, a sensible one that nobody has measured in people taking both.
Froese is clear that her video isn't meant to encourage buying peptides online, only to explain the science for people who are doing it anyway. Putting the question to herself, whether this is the ultimate fat-loss pairing, her answer was "I mean kind of. Yeah. But it helps to know what each of them are doing." For more on where these two fit among everything else, see our where to start with peptides guide and the weight and metabolic health page.
Tesamorelin has a label and a prescriber behind it. Retatrutide has neither yet, and any vial of either one bought online is sold for research. You knew that, it's why you're reading this and not the label.
